Almost 3 Years Ago
1 Min Read
AFMD up 9%. A closer look at what's happening:
Shares of Affimed N.V. (AFMD) are trading 9% higher at a price of $3.02 at the time of this writing.
Affimed N.V. has been trading between a 52-week high of $7.35 and a 52-week low of $2.23. The stock has a market cap of $373 Million.
Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE®) molecules, which use patients' immune cells to destroy tumor cells.
Affimed N.V. has been trading between a 52-week high of $7.35 and a 52-week low of $2.23. The stock has a market cap of $373 Million.
Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE®) molecules, which use patients' immune cells to destroy tumor cells.
Headlines
7 Undervalued Biotech Stocks to Buy Before They Boom
InvestorPlace 07-25-22
6 Blue-Chip Stocks to Sell Now
InvestorPlace 07-18-22
Affimed N.V. (NASDAQ: AFMD) Stock: Performance and Outlook
Marketing Sentinel 07-06-22
Affimed Establishes Scientific Advisory Board
Wallstreet:Online 06-30-22
Affimed Stock: Preparing For Key Inflection Points (NASDAQ:AFMD)
Seeking Alpha 06-29-22
Recommended Articles
